Relationship between chemotherapy and CH mutations. (A) Per gene contribution of platinum-associated mutational signatures to 749 post-platinum mutations in 655 patients with cancer (Bolton et al).¹¹ A small fraction (6 mutations from 5 patients) is included from clonal driver mutations in post-platinum tMN whole genomes. (B) Swimmer plot depicting the timing of CH assessment in relation to malignant diagnoses and transplant dates for tested samples in the WGS cohort. Latency reflects the time from the diagnosis of the primary tumor to the diagnosis of therapy-related malignancy. All samples were collected before melphalan administration with the exception of IID_H198319.